Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Keen Hun Tai"'
Autor:
Andrew Kneebone, Sandra Turner, George Hruby, Thomas Eade, Jeremy T. Booth, Keen Hun Tai, Amy Hayden, Paul J. Keall, Ricky O'Brien, Doan Trang Nguyen, Shankar Siva, Per Rugaard Poulsen, Peter B. Greer, Jarad Martin, Trevor Moodie, Nicholas Hardcastle, Emily A. Hewson
Publikováno v:
Hewson, E A, Nguyen, D T, O'Brien, R, Poulsen, P R, Booth, J T, Greer, P, Eade, T, Kneebone, A, Hruby, G, Moodie, T, Hayden, A J, Turner, S L, Hardcastle, N, Siva, S, Tai, K H, Martin, J & Keall, P J 2020, ' Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial ', Radiotherapy and Oncology, vol. 151, pp. 234-241 . https://doi.org/10.1016/j.radonc.2020.08.010
Radiotherapy & Oncology
Radiotherapy & Oncology
PurposeStereotactic Ablative Radiotherapy (SABR) has recently emerged as a favourable treatment option for prostate cancer patients. With higher doses delivered over fewer fractions, motion adaptation is a requirement for accurate delivery of SABR. T
Autor:
David R. H. Christie, James W. Denham, John Attia, Judy Murray, Gillian M. Duchesne, Christopher Oldmeadow, Sandra Turner, Lizbeth Kenny, Brett Delahunt, Allison Steigler, Nirdosh Kumar Gogna, Keen Hun Tai, David Joseph, Tom Shannon, Annette Haworth, John Stanley, John H L Matthews, Rachel Kearvell, Nigel Spry, Chris Atkinson, Martin A. Ebert, David Lamb
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 106:693-702
To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced prostate cancer.Participants with locally advanced prostate cancer in the TROG 03.04
Autor:
Nathan Lawrentschuk, Michael S Hofman, Andrew Lim, Daniel Moon, Cristian Udovicich, Keen Hun Tai, Declan G. Murphy, Mathias Bressel, Mark Shaw, Shankar Siva, Jeremy Goad, Lisa Selbie, John Violet, Sarat Chander, Farshad Foroudi, Tomas Kron
Publikováno v:
European Urology. 74:455-462
Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for oligometastatic prostate cancer. However, limited prospective evidence is available. Objective To determine the safety and feasibility of single fraction SA
Publikováno v:
Radiotherapy and Oncology. 161:S685
Autor:
James W. Denham, Gillian M. Duchesne, David Lamb, David Joseph, Allison Steigler, Keen Hun Tai, David R. H. Christie, Swetha Sridharan, John H L Matthews, John Attia, Nigel Spry, Elizabeth G. Holliday, Chris Atkinson
Publikováno v:
Radiotherapy and Oncology. 121:98-102
Background It remains unclear whether eradication of oligometastases by stereotactic body radiation therapy or other means will result in cure or prolongation of survival in some cases, or merely provide palliation. We address this issue with prospec
Autor:
George Hruby, John Kipritidis, Thomas Eade, Doan Trang Nguyen, Sankar Arumugam, Andrew Kneebone, Shankar Siva, Emily A. Hewson, H. Ball, Val Gebski, Keen Hun Tai, Sandra Turner, Regina Bromley, Perry Hunter, Trevor Moodie, Jeremy T. Booth, Per Rugaard Poulsen, Lee Wilton, Peter B. Greer, Nicholas Hardcastle, J.C Martín, Paul J. Keall, Amy Hayden, R. O'Brien, Mark Sidhom
Publikováno v:
Radiotherapy and Oncology. 133:S442-S443
Autor:
Gillian M. Duchesne, David Joseph, James W. Denham, Suki Gill, John N. S. Matthews, John Attia, Judy Murray, Annette Haworth, Christopher Oldmeadow, A. Kennedy, Martin A. Ebert, Keen Hun Tai, Sandra Turner, Allison Steigler, Nigel Spry, Elizabeth G. Holliday, Nirdosh Kumar Gogna, Lizbeth Kenny, Brett Delahunt, Hendrick Tan, Rachel Kearvell, Chris Atkinson, David Lamb
Publikováno v:
ResearcherID
The relative effects of radiation dose escalation (RDE) and androgen suppression (AS) duration on local prostatic progression (LP) remain unclear.We addressed this in the TROG 03.04 RADAR trial by incorporating a RDE programme by stratification at ra
Autor:
Patrick Bowden, Scott Williams, Rohen White, Keen Hun Tai, Gillian M. Duchesne, Farshad Foroudi, Mathias Bressel, Richard Khor
Publikováno v:
Clinical Oncology. 27:16-21
Aims There are limited outcome data after radiotherapy treatment for clinically localised, castration-resistant prostate cancer. We report our single institution experience on patient outcomes in this group using high-dose palliative radiotherapy (HD
Autor:
Sandra Turner, Terry Diamond, Gillian M. Duchesne, Lizbeth Kenny, Christopher Oldmeadow, Brett Delahunt, David Joseph, Nigel Spry, David Lamb, Chris Atkinson, Allison Steigler, Keen Hun Tai, Nirdosh Kumar Gogna, David R. H. Christie, James W. Denham, John N. S. Matthews, John Attia
Publikováno v:
The Lancet Oncology. 15:1076-1089
Summary Background We investigated whether 18 months of androgen suppression plus radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of neoadjuvant androgen suppression plus radiotherapy with or without zoledr
Autor:
Madeleine King, Rosemary Smith, Shawn Malone, Gillian M. Duchesne, Keen Hun Tai, Patrick Cheung, Roger L. Milne, Catherine D'Este, Andrew Loblaw, Himu Lukka, Julie K. Bassett, Jeremy Millar, Gregory R. Pond, Henry H. Woo, Martin R. Stockler, Mark Frydenberg, Sandra Turner, Tom Pickles
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 102:S148
5018Background: The TOAD (TROG 03.06; NCT00110162) phase 3 randomized trial showed that immediate androgen deprivation therapy (IADT) improved overall survival (OS) and time to clinical progression...